Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Dario Ruscica, MD
AstraZeneca, Cambridge, UK
Study Director - Jérôme Fayette, MD
Centre Leon Berard
Principal Investigator - Roger B Cohen, MD
Abramson Cancer Center, Perelman Center for Advanced Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
127 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
CABA, Argentina
- Research Site
CABA, Argentina
- Research Site
CABA, Argentina
- Research Site
Camperdown, Australia
- Research Site
Elizabeth Vale, Australia
- Research Site
Heidelberg, Australia
- Research Site
Melbourne, Australia
- Research Site
Linz, Austria
- Research Site
Brussels, Belgium
- Research Site
Leuven, Belgium
- Research Site
Namur, Belgium
- Research Site
Roeselare, Belgium
- Research Site
Belo Horizonte, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Rio de Janeiro, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
Panagyurishte, Bulgaria
- Research Site
Plovdiv, Bulgaria
- Research Site
Sofia, Bulgaria
- Research Site
Victoria, British Columbia, Canada
- Research Site
Hamilton, Ontario, Canada
- Research Site
Toronto, Ontario, Canada
- Research Site
Toronto, Ontario, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Avignon, France
- Research Site
Bordeaux, France
- Research Site
Clermont-Ferrand, France
- Research Site
Dijon, France
- Research Site
Lyon, France
- Research Site
Marseille, France
- Research Site
Montpellier, France
- Research Site
Strasbourg, France
- Research Site
Berlin, Germany
- Research Site
Essen, Germany
- Research Site
Freiburg im Breisgau, Germany
- Research Site
Hanover, Germany
- Research Site
Leipzig, Germany
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Oct 2020
- Primary completion
- 11 May 2022
- Completion
- 24 Sept 2026
- Last update posted
- 1 Jun 2026
- Registered enrollment
- 370
- Registry id
- NCT04590963
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.